- Home
- ELAB vs RDHL Comparison
ELAB vs RDHL Comparison
Compare ELAB & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELAB | RDHL |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 3.9M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELAB | RDHL |
|---|---|---|
| Price | $3.40 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 270.2K | 69.6K |
| Earning Date | 03-27-2026 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $285,948.00 | ★ $9,550,000.00 |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 157.62 |
| 52 Week Low | $3.76 | $1.01 |
| 52 Week High | $99.72 | $7.44 |
Technical Indicators
Market Signals| Indicator | ELAB | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 23.36 | 46.78 |
| Support Level | $4.89 | $1.18 |
| Resistance Level | $5.60 | $1.26 |
| Average True Range (ATR) | 0.44 | 0.06 |
| MACD | -0.14 | 0.02 |
| Stochastic Oscillator | 9.04 | 65.22 |
Price Performance
Historical ComparisonAbout ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.